Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewDiscordant lymphoma consisting of mediastinal large B-cell lymphoma and nodular sclerosis Hodgkin lymphoma in the right supraclavicular lymph nodes: a case reportMature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Primary mediastinal large B-cell lymphoma.Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.Primary mediastinal lymphoma: diagnosis and treatment options.Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines.JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC.Structural genomic alterations in primary mediastinal large B-cell lymphoma.Programmed death-1 & its ligands: promising targets for cancer immunotherapy.Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.Mechanisms underlying the association between obesity and Hodgkin lymphoma.Activating STAT6 mutations in follicular lymphoma.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.The promise of Janus kinase inhibitors in the treatment of hematological malignancies.HiJAKing the epigenome in leukemia and lymphoma.Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma.Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.Maybe we don't know JAK?Targeting STAT6 in PMBL.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases.Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma.Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification.A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models.Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model.Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model.The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies.Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemiasOxymatrine exhibits anti-tumor activity in gastric cancer through inhibition of IL-21R-mediated JAK2/STAT3 pathway
P2860
Q27304386-53588432-960D-4A1A-9D8F-AEA24FAF8454Q28072524-BDF2C821-3DDE-4671-A2DA-4D508A46F589Q30240133-0B23EBF5-A7D7-4519-9D33-F8BC0F16E4BBQ34266819-3A2831D2-26E8-43D3-B434-33E8410DC178Q34301568-87C01543-53B9-4465-84CD-89DE351AA28FQ34455499-5EA9F9C1-F045-476C-9189-E05D7A705217Q34802443-2E580A10-8B15-4E76-86A2-7F6BF7FFC045Q35850206-801D1106-097A-4F44-9A73-7ACC433459A8Q35987345-A8938832-6687-4A7F-B23C-D59DC47E5F27Q36413493-5A06A60B-636D-4172-89C0-733B45BC9B8EQ36522770-01252F48-47E2-422F-A604-535A716EF005Q37600589-338EE400-E62C-41AC-B0F9-203B60059285Q37675926-DCA695BF-301A-463B-B54A-50B4D62B0219Q38267888-1E0A8E2E-B4CD-4BF0-ABC6-2869BBB40FCBQ38562062-D1482CB9-2011-426C-993F-B2A7A416F6B7Q38754419-827133C3-175F-47B4-8643-FE6218D198E0Q38874291-F4CE3717-CF64-4E8C-874E-8F11DDC93F7CQ38910560-1308988A-D332-4F91-A117-B23FBF36ECF3Q38937478-BC32E926-628B-479C-AA83-A9861922D8A1Q38996724-01E4D107-7DD7-459B-9451-0369890ACE7AQ39135290-B4312D1C-3566-4E98-80C6-303A2B80901FQ39170500-F7D8300D-C3B2-4215-9A6A-020CEE3D54BEQ39237403-35E92E7E-9ADD-4978-8739-783A378C8D51Q39706167-B12FD7B4-A220-442D-B294-12D6A8CB6E5AQ41356776-E03CADBF-41B8-4CCB-9034-CF01FF95CF30Q41880157-669D191E-2220-491D-BDEA-A0E49C3E7ECDQ42950480-37F98745-D52B-440C-BECC-269F04EB59D7Q47120629-EB6BD9E0-BD30-4771-8FBA-2914CF8C4678Q47140442-9894D193-0D4E-463D-AB98-52BCECB928D2Q47270193-9B20F52E-4230-4008-9DF5-BFE7CBFDD7F1Q48330476-B235B679-0150-4491-B972-6F3BC2BC666CQ49416991-DDD5732D-EC9E-4FFA-8AB2-D5278A044405Q49912597-44D32AA9-9B2F-47E7-AD0D-7BE39085951BQ52668197-4E79E51E-D7F9-445A-BB59-2E5AD7C4248AQ52718917-656D38DD-F423-4862-8FB1-608A4978F917Q53008515-F59C8198-D694-4829-B6E6-A54A482698A0Q54213148-11E430A5-6878-4C42-B2F5-CAB905425E8EQ54216481-0DB518EC-1DB5-4777-BBC5-CFC787E74584Q57272422-9739ADA7-4DC6-4086-BBAC-746E7B41F64BQ58782158-17A3829B-56EE-4B17-A6A9-37384C1EDBD4
P2860
Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Selective JAK2 inhibition spec ...... a growth in vitro and in vivo.
@en
Selective JAK2 inhibition spec ...... a growth in vitro and in vivo.
@nl
type
label
Selective JAK2 inhibition spec ...... a growth in vitro and in vivo.
@en
Selective JAK2 inhibition spec ...... a growth in vitro and in vivo.
@nl
prefLabel
Selective JAK2 inhibition spec ...... a growth in vitro and in vivo.
@en
Selective JAK2 inhibition spec ...... a growth in vitro and in vivo.
@nl
P2093
P2860
P1476
Selective JAK2 inhibition spec ...... a growth in vitro and in vivo.
@en
P2093
Bjoern Chapuy
Heather H Sun
Margaret A Shipp
Scott J Rodig
Stefano Monti
Yansheng Hao
P2860
P304
P356
10.1158/1078-0432.CCR-13-3007
P407
P577
2014-03-07T00:00:00Z